Donma and Donma have argued that in vivo low selenite supplementation has pro-adipogenic effects via the increase in PPARγ signaling in adipocytes, which is associated with SELENOP [67] and that high selenite supply could present anti-obesity effects via the decrease PPARγ signaling; therefore, the development of lipophilic Se compounds capable of binding PPARγ could be a particular interesting approach. The gene discussed is SELENOP; the disease is obesity disorder.